Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel+BEP (T-BEP) vs BEP in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial

NCT07847190 is registered in ClinicalTrials.gov with Blokhin's Russian Cancer Research Center as lead sponsor.

NCT NCT07847190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07847190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel+BEP (T-BEP) vs BEP in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial
Lead sponsor
Blokhin's Russian Cancer Research Center
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2024
Completion date
October 31, 2029
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell cancer metastatic